Contraindications and caution for using dasatinib

Dasatinib (trade name Sprycel/Sprycel), as a tyrosine kinase inhibitor, is widely used to treat certain types of leukemia. However, like other medications, it does not work for everyone. The following is a detailed description of the contraindications of dasatinib and those who should use it with caution.

1. Contraindications:

This medication is strictly contraindicated in patients who are allergic to dasatinib or any of its components. Allergic reactions may include, but are not limited to, hives, difficulty breathing, and swelling of the face or throat. Patients should inform their doctor in detail about their allergic history before use to ensure safety. If the above symptoms occur after taking the medicine, please seek medical attention immediately.

2. Use with caution:

1. Patients with a history of cardiovascular disease or risk factors: Patients receiving dasatinib may experience cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events. If acute signs or symptoms of a cardiovascular event occur, patients should seek immediate medical attention. The patient's cardiovascular status and risk factors should be assessed before treatment, and cardiovascular monitoring and management should be performed during treatment.

2. Patients with fluid retention or congestive heart failure: Patients receiving dasatinib may experience fluid retention, which may manifest as pericardial effusion, pleural effusion, etc. Dasatinib should be used with caution in these patients and requires close monitoring and management. Interrupt, reduce dose, or discontinue treatment if necessary.

3. Patients with bone marrow suppression: Since dasatinib may cause thrombocytopenia, aplastic anemia, etc., patients with existing bone marrow suppression should be cautious when using it and have complete blood counts performed regularly.

4. Patients with impaired liver function: It is recommended that these patients use dasatinib with caution, and the drug dosage may need to be adjusted according to liver function.

5. Patients with underlying cardiopulmonary disease: Dasatinib may increase the risk of pulmonary hypertension. Such patients should use it with caution and discontinue medication immediately if relevant symptoms occur.

6. Patients with electrolyte disorders or a history of cardiac arrhythmias: Dasatinib may be prolongedQT interval. Particular caution should be exercised in patients with congenital long QT syndrome, hypokalemia, hypomagnesemia, or a history of cardiac arrhythmias who are taking antiarrhythmic drugs. Hypokalemia or hypomagnesemia should be corrected before initiating treatment. Patients at risk should be monitored with EKG prior to treatment and periodically as clinically indicated. Dosage adjustment may be required.

In conclusion, although dasatinib has shown significant efficacy in the treatment of leukemia, its use must take into account the patient's specific circumstances and potential risks. Doctors should develop an individualized treatment plan based on the patient's overall health and risk factors. It is reported that dasatinib is already on the market in my country. Please consult local hospitals for specific prices. In addition, its generic versions are available in countries such as India, providing patients with multiple options.